Inmune Bio, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Inmune Bio, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q3 2024.
  • Inmune Bio, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$12.1M, a 41.2% decline year-over-year.
  • Inmune Bio, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$41.3M, a 50.4% decline year-over-year.
  • Inmune Bio, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$30M, a 9.92% decline from 2022.
  • Inmune Bio, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$27.3M, a 10% increase from 2021.
  • Inmune Bio, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$30.3M, a 151% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$41.3M -$12.1M -$3.53M -41.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 -$37.7M -$9.75M -$3.25M -49.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-10-31
Q1 2024 -$34.5M -$11M -$4.49M -68.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-10-31
Q4 2023 -$30M -$8.41M -$2.58M -44.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$27.4M -$8.56M -$838K -10.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 -$26.6M -$6.5M +$337K +4.93% Apr 1, 2023 Jun 30, 2023 10-Q 2024-10-31
Q1 2023 -$26.9M -$6.54M +$367K +5.32% Jan 1, 2023 Mar 31, 2023 10-Q 2024-10-31
Q4 2022 -$27.3M -$5.83M +$3.84M +39.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$31.1M -$7.73M +$1.73M +18.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$32.9M -$6.84M -$183K -2.75% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-01
Q1 2022 -$32.7M -$6.9M -$2.35M -51.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-01
Q4 2021 -$30.3M -$9.67M -$6.47M -202% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-02
Q3 2021 -$23.9M -$9.46M -$4.74M -101% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$19.1M -$6.66M -$4.55M -216% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 -$14.6M -$4.56M -$2.49M -120% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$12.1M -$3.2M -$886K -38.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-03
Q3 2020 -$11.2M -$4.72M -$1.65M -53.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$9.56M -$2.11M -$1.72M -438% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$7.85M -$2.07M -$169K -8.89% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$7.68M -$2.32M -$438K -23.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-04
Q3 2019 -$7.24M -$3.07M -$1.53M -99.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$5.71M -$392K +$5.78M +93.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$11.5M -$1.9M +$945K +33.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$12.4M -$1.88M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 -$1.54M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$6.17M Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-08
Q1 2018 -$2.85M Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.